ArticleTherapeutic advances in medical oncology2026
Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether the HLX-02 plus pertuzumab offers superior efficacy compared to the HLX-02 plus pyrotinib in the early-stage setting remains unclear, highlighting a critical gap in evidence for optimizing neoadjuvant therapy selection. Objective: To compare the efficacy and safety of neoadjuvant chemotherapy regimens combining the trastuzumab biosimilar HLX-02 with either pertuzumab or pyrotinib in patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Design: This is a retrospective cohort study. Methods: This retrospective cohort study enrolled patients with HER2-positive breast cancer who received neoadjuvant therapy at The First Affiliated Hospital of University of Science and Technology of China between October 2021 and July 2024. Participants were divided into two treatment groups: those receiving docetaxel, carboplatin, HLX‑02 plus pertuzumab (TCbHP group), and those receiving docetaxel, carboplatin, HLX‑02 (a Results: A total of 101 patients were initially included. After PSM, 55 patients were selected (TCbHP group: Conclusion: Both HLX‑02‑based neoadjuvant regimens exhibited comparable efficacy in achieving pCR in patients with HER2‑positive breast cancer. These findings indicate that HLX‑02, whether combined with pertuzumab or pyrotinib, represents a viable neoadjuvant strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.